業 績 一 覧 2026

原著

1. Hirano T, Sakai K, Yoshimura T, Chiyoda T, Nakamura K, Aimono E, Kawaida M, Nishihara H, Susumu N, Aoki D, Yamagami W. Prognostic biomarker of fertility-preserving hormonal therapy based on multigene panel testing for endometrial cancer. Cancer Sci. 2026 Jan;117(1):236-245.
2. Jisaka M, Nakamura K, Chiyoda T, Iwata T, Masuda K, Kawano R, Funata S, Takamatsu R, Nishihara H, Yamagami W. Secondary POLE mutation drives metastasis in hereditary breast and ovarian cancer: Revealing fallopian tube ultramutation. JCO Precis Oncol. 2026 Jan:10:e2500382.
3. Kurihara M, Iwabuchi Y, Yamada Y, Shimizu A, Yoshimura T, Sakai K, Chiyoda T, Nakamura K, Nishihara H, Yamagami W, Jinzaki M. Elevated 18F-FDG uptake in non-metastatic lymph nodes of POLE-mutated endometrial cancer on PET/CT. Eur J Radiol. 2026 Feb:195:112620.
4. Sonoda K, Hayashi H, Kitago M, Abe Y, Hasegawa Y, Hori S, Tanaka M, Nakano Y, Nishihara H, Kitagawa Y. Genomic concordance between primary and oligo-recurrent lesions in pancreatobiliary cancer. J Hepatobiliary Pancreat Sci. 2026 Jan 19.
5. Nakamura K, Tamura R, Sogano J, Yo M, Karatsu K, Nguyen TH, Takamatsu R, Misu K, Fukada I, Kosaki K, Ueno T, Nishihara H, Toda M. Diverse NF2 alterations in cranial schwannomas: a two-case series of germline whole-gene deletion and somatic in-frame deletion. Brain Tumor Pathol. 2026 Jan 21.

症例報告

1. Yokota K, Kosaka T, Daimon T, Fujiwara S, Nakamura K, Nishihara H, Oya M. Drastic response to olaparib in a patient with metastatic castration-resistant prostate cancer harboring BRCA2 alterations and near-threshold tumor mutational burden IJU Case Rep. 2026 Jan 28;9(2):e70144.